Vestibular migraine and patent foramen ovale are closely related conditions with linked incidence rates.This systematic review presents the potential pathophysiological mechanisms underlying the association of patent foramen ovale with vestibular migraine，delves into the clinical features and classifications of vestibular migraine as well as the shunt status and anatomical features of patent foramen ovale，and also discusses the outcome of vestibular migraine following a patent foramen ovale closure.Vasoactive peptide，microemboli，inflammation，and genetic theories have been proposed for the association of the two conditions.Although most studies support a link between vestibular migraine and patent foramen ovale，evidence is lacking to prove that patients with vestibular migraine can gain significant benefits from a patent foramen ovale closure，and moreover，the surgery-related serious adverse events and risks，such as atrial fibrillation and new-onset headache，need careful consideration.

Background: Serum immunoglobulin A antibodies against Epstein–Barr virus (EBV), viral capsid antigen (VCA?IgA) and early antigen (EA?IgA), are used to screen for nasopharyngeal carcinoma (NPC) in endemic areas. However, their routine use has been questioned because of a lack of specificity. This study aimed to determine the distributions of different subtypes of antibody and to illustrate how the natural variation patterns affect the specificity of screening in non?NPC participants. Methods: The distribution of baseline VCA?IgA was analyzed between sexes and across 10?year age groups in 18,286 non?NPC participants using Chi square tests. Fluctuations in the VCA?IgA level were assessed in 1056 non?NPC participants with at least two retests in the first 5?year period (1987–1992) after the initial screening using the Kaplan–Meier method. Results: The titers of VCA?IgA increased with age (P < 0.001). Using a previous serological definition of high NPC risk, nasopharyngeal endoscopy and/or nasopharyngeal biopsy would be recommended in 55.5% of the non?NPC partici?pants with an initial VCA?IgA?positive status and in 20.6% with an initial negative status during the 5?year follow?up. However, seroconversions were common; 85.2% of the participants with a VCA?IgA?positive status at baseline con?verted to negative, and all VCA?IgA?negative participants changed to positive at least once during the 5?year follow?up. The EA?IgA status had a high seroconversion probability (100%) from positive to negative; however, it had a low probability (19.6%) from negative to positive. Conclusions: Age? and sex?specific cutoff titer values for serum anti?EBV antibodies as well as their specific titer fluc?tuation patterns should be considered when defining high NPC risk criteria for follow?up diagnostics and monitoring.